These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38106767)

  • 21. Retrospective evaluation of enoxaparin dosing in patients 48 weeks' postmenstrual age or younger in a neonatal intensive care unit.
    Hicks JK; Shelton CM; Sahni JK; Christensen ML
    Ann Pharmacother; 2012; 46(7-8):943-51. PubMed ID: 22828970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment of prophylactic enoxaparin dosing recommendations to achieve targeted anti-factor Xa concentrations in children with CHD.
    Israel EN; Thomas CA; Mastropietro CW
    Cardiol Young; 2018 May; 28(5):715-718. PubMed ID: 29490713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of anti-factor Xa concentrations using a body mass index-based enoxaparin dosing protocol for venous thromboembolism prophylaxis in trauma patients.
    O'Keefe MM; Carver TW; Herrmann DJ; Prom A; Hubbard S; Rein LE; Peppard WJ
    Pharmacotherapy; 2022 Mar; 42(3):216-223. PubMed ID: 35100448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of Optimal Weight-Based Enoxaparin Dosing and Associated Clinical Factors for Achieving Therapeutic Anti-Xa Assays for Deep Venous Thrombosis Prophylaxis.
    Bethea A; Samanta D; Deshaies D; Richmond BK
    J Am Coll Surg; 2019 Sep; 229(3):295-304. PubMed ID: 30954541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enoxaparin Dose Requirements to Achieve Therapeutic Low-molecular-weight Heparin Anti-factor Xa Levels in Infants and Young Children.
    Wysocki EL; Kuhn A; Steinbrenner J; Tyrrell L; Abdel-Rasoul M; Dunn A; Cloyd C
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e946-e950. PubMed ID: 33512867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?
    Sanchez de Toledo J; Gunawardena S; Munoz R; Orr R; Berry D; Sonderman S; Krallman S; Shiderly D; Wang L; Wearden P; Morell VO; Chrysostomou C
    Cardiol Young; 2010 Apr; 20(2):138-43. PubMed ID: 20199704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased Enoxaparin Dosing Requirements for Treatment of Deep Vein Thrombosis in a Severely Burned Patient: Case Report and Literature Review.
    Yost RJ; Haan BJ; Mangan KC
    Pharmacotherapy; 2018 Nov; 38(11):e82-e86. PubMed ID: 30129107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients.
    Costantini TW; Min E; Box K; Tran V; Winfield RD; Fortlage D; Doucet J; Bansal V; Coimbra R
    J Trauma Acute Care Surg; 2013 Jan; 74(1):128-33; discussion 134-5. PubMed ID: 23271087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
    Bauman ME; Black KL; Bauman ML; Belletrutti M; Bajzar L; Massicotte MP
    Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. One size does not fit all: Sex bias in pharmacologic venous thromboembolism prophylaxis.
    Modi RN; Borst JM; Kirchberg TN; Box K; Smith AM; Godat LN; Doucet JJ; Costantini TW; Berndtson AE
    J Trauma Acute Care Surg; 2023 Jan; 94(1):78-85. PubMed ID: 35787601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enoxaparin thromboprophylaxis in hospitalized obese pediatric patients.
    Yim J; Jahan A; Braykov N; Murphy ND; Woods GM
    Pediatr Blood Cancer; 2024 Mar; ():e30942. PubMed ID: 38486078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of anti-xa monitoring in children receiving enoxaparin for therapeutic anticoagulation.
    Leung M; Ho SH; Hamilton DP; Wu JK; Dix DB; Wadsworth LD; Ensom MH
    J Pediatr Pharmacol Ther; 2005 Jan; 10(1):43-50. PubMed ID: 23118625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low molecular weight heparin dosing and monitoring in solid organ transplant recipients.
    Moten MA; Gaber AO; Putney D; Patel SJ
    Clin Transplant; 2013; 27(6):852-7. PubMed ID: 24033530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
    Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS
    Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of anti-factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children.
    Greene LA; Law C; Jung M; Walton S; Ignjatovic V; Monagle P; Raffini LJ
    J Thromb Haemost; 2014 Sep; 12(9):1554-7. PubMed ID: 24943261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
    Corder A; Held K; Oschman A
    Pediatr Blood Cancer; 2014 Jun; 61(6):1063-7. PubMed ID: 24375987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin.
    Richard AA; Kim S; Moffett BS; Bomgaars L; Mahoney D; Yee DL
    J Pediatr; 2013 Feb; 162(2):293-6. PubMed ID: 22959138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weight-Based Dosing for Once-Daily Enoxaparin Cannot Provide Adequate Anticoagulation for Venous Thromboembolism Prophylaxis.
    Pannucci CJ; Hunt MM; Fleming KI; Prazak AM
    Plast Reconstr Surg; 2017 Oct; 140(4):815-822. PubMed ID: 28953735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairment.
    Chamoun N; Ghanem H; Hachem A; Hariri E; Lteif C; Mansour H; Dimassi H; Zalloum R; Ghanem G
    BMC Pharmacol Toxicol; 2019 May; 20(1):27. PubMed ID: 31064405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Supratherapeutic anticoagulation from low-molecular-weight heparin in lung transplant recipients.
    Singer JP; Huang MY; Hui C; Blanc PD; Boettger RF; Golden J; Watkins K; Hoopes C; Leard LE
    J Heart Lung Transplant; 2010 Sep; 29(9):1009-13. PubMed ID: 20627627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.